- Source : Press Release
- Date : 2021-06-10
- Event type : Phase 1
- Companies : TICEBA GmbH
Epidermolysis Bullosa (EB): Orphan Drug Designation from FDA and EMA Granted
The medicinal drug product tested in international phase I/IIa clinical trial has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).